Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 16 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Markers of hepatocellular carcinoma in Hep C-related cirrhosis

Anti-Hep B core antigen-positive results on serologic testing are a marker of hepatocellular carcinoma risk in Hep C virus-related cirrhosis, shows this month's Annals of Internal Medicine.

News image

fiogf49gjkf04

Previous exposure to Hepatitis B virus and occult Hepatitis B virus infection may have an role in hepatocellular carcinoma in patients with chronic liver disease related to Hepatitis C virus.

Dr Kazuki Ikeda and colleagues from Japan prospectively studied the association between antibody to Hepatitis B core antigen and clinical outcomes in patients with Hepatitis C virus-related chronic liver disease.

Hepatocellular carcinoma was diagnosed in 60% with anti-Hep B core antigen
Annals of Internal Medicine

The team assessd 872 patients with chronic Hepatitis C virus infection, of which 597 had chronic Hepatitis, and 275 had cirrhosis.

The research team measured incidence of hepatocellular carcinoma on follow-up from 1995 to 2005.

Only 846 of the 872 enrolled patients were followed up.

The team found that hepatocellular carcinoma occurred in 28% of patients.

Among patients with cirrhosis, hepatocellular carcinoma was diagnosed in 60% with anti-Hepatitis B core antigen.

The researchers noted that hepatocellular carcinoma was diagnosed in 45% without Hepatitis B virus-related serologic markers.

Of 224 patients with chronic hepatitis who had interferon monotherapy, 41% had sustained or transient disappearance of Hepatitis C virus RNA.

None of the anti-Hepatitis B core antigen-negative patients who had a virologic response to interferon therapy developed hepatocellular carcinoma.

The researchers observed that cancer was diagnosed in 4 of 37 anti-Hepatitis B core antigen -positive patients with a virologic response to interferon.

On further analysis, the team found that anti-Hepatitis B core antigen-positive results on serologic testing was an independent risk factor in patients with cirrhosis.

The researchers undertook only 1 assessment of smoking and alcohol consumption at study entry.

The team reported that they did not precisely determine the duration of smoking or alcohol use.

Dr Ikeda's team concluded, " Anti-Hepatitis B core antigen-positive results on serologic testing are a marker of high risk for hepatocellular carcinoma among patients with Hepatitis C virus-related cirrhosis."

"Interferon therapy might be less effective in preventing hepatocellular carcinoma among patients with chronic Hepatitis C who are anti-Hepatitis B core antigen-positive."

Ann Int Med 2007: 146(9): 649-56
03 May 2007

Go to top of page Email this page Email this page to a colleague

 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 16 January 2018 
Bundle of care in GI cancer surgery
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 15 January 2018 
Risks of death after liver transplants for liver cancer
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Colonoscopy after colorectal cancer resection
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
PPI and Alzheimer's disease
 21 December 2017 
Health management for IBD
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 05 December 2017 
Childhood obesity into adulthood

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us